menu
    • menu

    Company profile for Yamo Pharmaceuticals

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Yamo Pharmaceuticals a clinical-stage pharmaceutical company which has developed L1-79, an oral treatment that appears to impact the core symptoms of autism, including socialization and communication developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic s...
    Yamo Pharmaceuticals a clinical-stage pharmaceutical company which has developed L1-79, an oral treatment that appears to impact the core symptoms of autism, including socialization and communication developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic symptoms of autism.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Yamo PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    400 Madison Ave, Rm 11A, New York City, New York, 10017
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.yamopharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Yamo Pharma Shows Positive Autism Data for L1-79
    Yamo Pharma Shows Positive Autism Data for L1-79

    08 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/08/3077235/0/en/Yamo-Pharma-Presents-Statistically-Significant-Phase-2-Autism-Results-for-L1-79-at-INSAR-2025.html

    GLOBENEWSWIRE
    08 May 2025
    Share Share
    Yamo Reports Positive Phase 2 Results For Autism Treatment L1-79
    Yamo Reports Positive Phase 2 Results For Autism Treatment L1-79

    30 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/30/2920974/0/en/Yamo-Pharmaceuticals-Announces-Positive-Topline-Results-from-Phase-2-Study-of-L1-79-for-the-Treatment-of-the-Core-Symptoms-of-Autism.html

    GLOBENEWSWIRE
    30 Jul 2024
    Share Share
    Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79
    Yamo Pharmaceuticals Enrolls Final Patient in Phase 2 Study Evaluating L1-79

    20 Nov 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/11/20/2783221/0/en/Yamo-Pharmaceuticals-Enrolls-Final-Patient-in-Phase-2-Study-Evaluating-L1-79-to-Treat-the-Core-Symptoms-of-Autism-Spectrum-Disorder.html

    GLOBENEWSWIRE
    20 Nov 2023
    Share Share
    Yamo Pharma doses first subject in Phase II autism spectrum disorder trial
    Yamo Pharma doses first subject in Phase II autism spectrum disorder trial

    28 Jan 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/yamo-autism-therapytrial/

    CLINICALTRIALSARENA
    28 Jan 2022
    Share Share
    Yamo Pharma Begins Enrollment in Phase 2 Study of L1-79 in ASD
    Yamo Pharma Begins Enrollment in Phase 2 Study of L1-79 in ASD

    27 Jan 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/01/27/2374277/0/en/Yamo-Pharmaceuticals-Announces-Enrollment-of-First-Patient-in-Phase-2-Study-of-L1-79-in-Autism-Spectrum-Disorder.html

    GLOBENEWSWIRE
    27 Jan 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search